The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 2, 2013, Pages 235-242

  Kayabasi, H ^a   Yilmaz, Z ^b   Sit, D ^c   Kadiroglu, A K ^b   Yilmaz, E ^b  

^a Yalova Devlet Hastanesi   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

^c BAGCILAR TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Hemodialysis; Inflammation; Losartan; Oxidative stres

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FERRITIN; FIBRINOGEN; LOSARTAN; THIOL GROUP; TROLOX C;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; TREATMENT DURATION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 84878584999     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. LUKE RG. Chronic renal failure-a vasculopathic state. N Engl J Med 1998; 339: 841-843.
2. LOCATELLI F, MARCELLI D, CONTE F, D'AMICO M, DEL VECCHIO L, LIMIDO A, MALBERTI F, SPOTTI D. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15(Suppl 5): S69-S80
3. LEVEY AS, BETO JA, CORONADO BE, EKNOYAN G, FOLEY RN, KASISKE BL, KLAG MJ, MAILLOUX LU, MANSKE CL, MEYER KB, PARFREY PS, PFEFFER MA, WENGER NK, WILSON PW, WRIGHT JT JR. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906
4. BRUNNER FP. Selwood NH on behalf of the EDTA Registry Committee. Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 1992; 42(Suppl 38): S4-S15.
5. ZOCCALI C. Cardiovascular risk in uraemic patients- is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-457.
6. EREL O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-119.
7. MIYAZAWA T. Determination of phospholipids hydroperoxides in human blood plasma by a chemiluminescence's- HPLC assay. Free Radic Biol Med 1989; 7: 209-217.
8. HARMA M, HARMA M, EREL O. Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly 2003; 133: 563-566.
9. DESCAMPS-LATSCHA B, DRÜEKE T, WITKO-SARSAT V. Dialysis- induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001; 14: 193-199.
10. CANAUD B, CRISTOL JP, MORENA M, LERAY-MORAGUES H, BOSC J, VAUSSENAT F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 1999; 17: 99-106.
11. NGUYEN A, LETHIAS C, ZINGRAFF J, HERBELIN A, NARET C, DESCAMPS-LATSCHA B. Hemodialysis membraneinduced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985; 28: 158-167.
12. DESCAMPS-LATSCHA B, GOLDFARB B, NGUYEN AT, LANDAIS P, LONDON G, HAEFFNER-CAVAILLON N, JACQUOF C, HERBELIN A, KAZATCHKINE M. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: a randomized prospective study. Nephron 1991; 59: 279-285.
13. LOCATELLI F, CANAUD B, ECKARDT KU, STENVINKEL P, WANNER C, ZOCCALI C. Oxidative stress in endstage renal disease: an emerging threat to patient outcome, Consensus Paper. Nephrol Dial Transplant 2003; 18: 1272-1280.
14. OGAWA S, MORI T, NAKO K, KATO T, TAKEUCHI K, ITO S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.Hypertension 2006; 47: 699-705.
15. BOAZ M, MATAS Z, BIRO A, KATZIR Z, GREEN M, FAIRNAV M, SMETANA S. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56:1978-1983.
16. TANIYAMA Y, GRIENDLING KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-1081.
17. TOUYZ RM. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz J Med Biol Res 2004; 37: 1263-1273.
18. TOUYZ RM, SCHIFFRIN EL. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 1999; 34(4 Pt 2): 976-982.
19. ONOZATO ML, TOJO A, GOTO A, FUJITA T, WILCOX CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61: 186-194.
20. FAN Q, LIAO J, KOBAYASHI M, YAMASHITA M, GU L, GOHDA T, SUZUKI Y, WANG LN, HORIKOSHI S, TOMINO Y. Candesartan reduced advanced glycation endproducts accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020.
21. KEDZIORA-KARNATOWSKA KZ, LUCIAK M, POSZKOWSKI J. Lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney: effect of treatment with angiotensin convertase inhibitors. IUBMB Life 2000; 49: 303-307.
22. DE CAVANAGH EM, INSERRA F, FERDER L, FRAGA CG. Enalapril and captopril enhance gluthatione-dependent antioxidant defenses in mouse tissues. Am J Physiol Regul Integr Comp Physiol 2000; 278: R572-R577.
23. ALTUNTAS Y, GUVEN M, INCE E, ACBAY O, CANER M, KANIGUR-SULTUYBEK G. The in vitro effects of captopril on the levels of lipid peroxidation and gluthatione of erythrocytes in type II diabetes. J Basic Clin Physiol Pharmacol 1995; 6: 281-288.
24. ANDERSEN S, TARNOW L, ROSSING P, HANSEN BV, PARVING HH. Renoprotective effects of angiotensin II receptor blockage in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606.
25. LAZANO J, LIISTERRI JL, AZNAR J, REDON J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16(Suppl l): 85-89.
26. NGUYEN-KHOA T, MASSY ZA, DE BANDT JP, KEBEDE M, SALAMA L, LAMBREY G, WITKO-SARSAT V, DRÜEKE TB, LACOUR B, THÉVENIN M. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335-340.
27. HANDELMAN GJ, WALTER MF, ADHIKARLA R, GROSS J, DALLAL GE, LEVIN NW, BLUMBERG JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-1966.
28. MEZZANO D, PAIS EO, ARANDA E, PANES O, DOWNEY P, ORTIZ M, TAGLE R, GONZÁLEZ F, QUIROGA T, CACERES MS, LEIGHTON F, PEREIRA J. Inflammation, not homocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60: 1844-1850.
29. WI TKO-SARSAT V, FRI EDLANDER M, KHOA TN, CAPEILLERE-BLANDIN C, NGUYEN AT, CANTELOUP S, DAYER JM, JUNGERS P, DRÜEKE T, DESCAMPS-LATSCHA B. Advanced oxidation protein products as a novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
30. ZHANG R, BRENNAN M-L, FU X, AVILES RJ, PEARCE GL, PENN MS, TOPOL EJ, SPRECHER DL, HAZEN SL. Association between myeloperoxidase levels and risk of coronary artery disease. J Am Med Assoc 2001; 286: 2136-2142.
31. PECOITYS-FILHO R, STENVINKEL P, MARCHLEWSKA A, HEIMBURGER O, BARANY P, HOFF CM HOLMES CJ, SULIMAN M, LINDHOLM B, SCHALLING M, NORDFORS L. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int 2003; 84: S172- 176.
32. KEIDAR S, ATTIAS J, SMITH J. The angiotensin II receptor antagonist losartan inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 1997; 236: 622-625.
33. KHAPER N, SIGNAL PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptor in MI rats. J Am Coll Cardiol 2001; 37: 1461-1466.
34. TANDON R, SINHA MK, GARG H, KHANNA R, KHANNA HD. Oxidative stress in patients with essential hypertension. Natl Med J India 2005; 18: 297-299.